A senior executive at Evolus, Inc. (NASDAQ:EOLS) completed a stock sale this month to satisfy tax withholding tied to recently vested equity awards. On March 17, 2026, Avelar Rui, the company's Chief Medical Officer and Head of Research and Development, sold 29,996 shares of Evolus common stock for roughly $146,629. The shares transacted at prices ranging from $4.8874 to $4.945 per share.
The disposition followed the vesting and settlement of performance restricted stock units on March 16, 2026. As a result of that vesting event, 8,804 shares of Evolus common stock were issued to Rui at an acquisition price of $0.
After these movements, Rui's direct ownership in Evolus stands at 430,542 shares. The company's stock has fallen 64% over the past year. According to InvestingPro analysis cited in company reporting, Evolus appears undervalued at current levels, and InvestingPro Tips noted that the stock suffered a significant decline over the last week, which is listed as one of several insights available to subscribers.
The March 17 sale was carried out under a Rule 10b5-1 trading plan. Company filings indicate the sale was intended to cover tax withholding obligations associated with the vesting of performance restricted stock units and restricted stock unit awards.
Separately, Evolus disclosed its fourth-quarter 2025 financial results. The company reported $90.3 million in revenue, narrowly missing the projected $90.75 million. This financial disclosure followed publication of the company's earnings call transcript.
There were also recent changes to the company's board. Vikram Malik was reclassified from a Class III director to a Class II director to preserve balance among the board classes following the departure of Simone Blank. The board accepted Malik's resignation as a Class III director effective immediately prior to his reappointment in the new class.
Company filings describe these governance steps as part of efforts to maintain stability in board composition. The equity transactions by the CMO, the revenue outcome for Q4 2025, and the board reclassification together outline the latest set of developments in Evolus's corporate and financial reporting.
Key points
- Avelar Rui sold 29,996 Evolus shares on March 17, 2026 for about $146,629 at prices between $4.8874 and $4.945.
- 8,804 shares were issued to Rui on March 16, 2026 as performance restricted stock units settled at a $0 acquisition price; Rui now directly holds 430,542 shares.
- Evolus reported $90.3 million in Q4 2025 revenue, a slight miss versus $90.75 million expected, and reclassified a board seat to preserve class balance after a director departure.
Risks and uncertainties
- The company's stock has declined 64% over the past year, indicating market volatility and risk for equity holders in the healthcare sector and broader markets.
- The narrow revenue shortfall for Q4 2025 represents an execution risk in near-term financial performance for Evolus and could affect investor sentiment in the healthcare and aesthetic medicine subsector.
- Board changes following a director departure create governance uncertainty as the company adjusts class structure, which may influence perceptions among corporate governance-focused investors.